Literature DB >> 24234946

Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus.

Elliott M Groves1, Katherine Yu, Nathan D Wong, Shaista Malik.   

Abstract

OPINION STATEMENT: Type II diabetes and metabolic syndrome are 2 intertwined conditions that are critical to the healthcare landscape in the United States and abroad. Patients with either diabetes or metabolic syndrome can have a dramatically increased risk of developing cardiovascular disease. Numerous treatment options have existed for some time, which include nonpharmacologic and pharmacologic therapies. In addition, within the last decade, a multiple of novel treatment options have emerged for the management of hyperglycemia in particular. By targeting novel pathways beyond the secretion and supply of insulin, these new therapeutics provide a valuable adjunct to the currently available therapies for diabetes and metabolic syndrome. Here we discuss the current guideline-driven usage of standard therapies with some novel indications. In addition, we discuss the novel therapies for the treatment of hyperglycemia, their mechanisms of action, and appropriate therapeutic indications.

Entities:  

Year:  2013        PMID: 24234946      PMCID: PMC4022706          DOI: 10.1007/s11936-013-0273-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  72 in total

1.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

Authors:  Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

Review 2.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

3.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

Authors:  C L Meinert; G L Knatterud; T E Prout; C R Klimt
Journal:  Diabetes       Date:  1970       Impact factor: 9.461

4.  Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.

Authors:  Harshal R Patil; Firas J Al Badarin; Hamza A Al Shami; Salman K Bhatti; Carl J Lavie; David S H Bell; James H O'Keefe
Journal:  Am J Cardiol       Date:  2012-06-15       Impact factor: 2.778

5.  Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

Authors:  Prakash Deedwania; Philip Barter; Rafael Carmena; Jean-Charles Fruchart; Scott M Grundy; Steven Haffner; John J P Kastelein; John C LaRosa; Holly Schachner; James Shepherd; David D Waters
Journal:  Lancet       Date:  2006-09-09       Impact factor: 79.321

6.  Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus.

Authors:  Roldano Scognamiglio; Christian Negut; Angelo Ramondo; Antonio Tiengo; Angelo Avogaro
Journal:  J Am Coll Cardiol       Date:  2005-12-09       Impact factor: 24.094

7.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

Review 8.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease.

Authors:  Oscar H Franco; Ewout W Steyerberg; Frank B Hu; Johan Mackenbach; Wilma Nusselder
Journal:  Arch Intern Med       Date:  2007-06-11

10.  Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Authors:  K Stenlöf; W T Cefalu; K-A Kim; M Alba; K Usiskin; C Tong; W Canovatchel; G Meininger
Journal:  Diabetes Obes Metab       Date:  2013-01-24       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.